Repatha review not quite Praluent mirror; dosing stands out
This article was originally published in Scrip
Executive Summary
While it may appear at first glance the FDA's review of Amgen's proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Repatha (evolocumab) mirrors in many ways what the agency said late last week about Sanofi's and Regeneron Pharmaceuticals' experimental drug in the same class, Praluent (alirocumab), regulators have identified some differences – mostly notably around the dosing of the products.